Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
X4 Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
XFOR
Nasdaq
8731
https://www.x4pharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for X4 Pharmaceuticals Inc
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jun 2nd, 2023 8:05 pm
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
- May 16th, 2023 8:01 pm
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
- May 16th, 2023 12:30 pm
Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review
- May 15th, 2023 8:44 am
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
- May 4th, 2023 10:05 am
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32%
- Apr 26th, 2023 4:32 pm
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
- Apr 26th, 2023 12:01 pm
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
- Apr 12th, 2023 12:00 pm
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Call Transcript
- Mar 24th, 2023 11:36 am
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- Mar 21st, 2023 10:05 am
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
- Mar 7th, 2023 1:01 pm
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
- Jan 31st, 2023 5:00 pm
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
- Dec 12th, 2022 1:30 pm
X4 Pharmaceuticals Prices $65.0 Million Public Offering
- Dec 7th, 2022 1:43 pm
X4 Pharmaceuticals Announces Proposed Public Offering
- Dec 6th, 2022 11:26 pm
X4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency Candidate
- Nov 30th, 2022 1:05 pm
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
- Nov 29th, 2022 9:01 pm
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) most popular amongst individual investors who own 40% of the shares, institutions hold 34%
- Nov 17th, 2022 2:51 pm
X4 Pharmaceuticals to Present at Stifel Healthcare Conference
- Nov 8th, 2022 1:00 pm
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Nov 3rd, 2022 10:05 am
Scroll